Home Apoptosis Ferroptosis

Ferroptosis Activators

Cat.No. Product Name Information Product Use Citations Product Validations
S8254 FIN56 FIN56 is a specific inducer of ferroptosis .
Cell Metab, 2025, S1550-4131(25)00149-4
Nat Commun, 2025, 16(1):2597
Mol Cell, 2025, 85(18):3474-3485.e5
S9663 iFSP1 iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1/AIFM2) with EC50 of 103 nM. This compound selectively induces ferroptosis in GPX4-knockout Pfa1 and HT1080 cells that overexpresses FSP1.Solutions are unstable and should be fresh-prepared.
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
Cell Death Dis, 2025, 16(1):190
Cell Rep, 2025, 44(9):116139
E0375 Ammonium ferric citrate Ammonium ferric citrate (Ferric ammonium citrate, Ammonium iron(III) citrate, Iron ammonium citrate, FerriSeltz) induces ferroptosis in non-small-cell lung carcinoma through the inhibition of GPX4-GSS/GSR-GGT axis activity.
J Virol, 2025, 99(9):e0097425
Theranostics, 2024, 14(16):6161-6184
Antioxidants (Basel), 2024, 13(4)430
E1812 N6F11 N6F11 is an inducer of ferroptosis. This compound is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation.
Biochem Biophys Res Commun, 2024, 740:151015
Science Translational Medicine, 2023, eadg3049
S1166 Cisplatin Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy.Solutions are unstable and should be fresh-prepared.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
Cell, 2025, S0092-8674(25)00291-0
Cancer Cell, 2025, S1535-6108(25)00223-5
Cell Stem Cell, 2025, S1934-5909(25)00265-6
Verified customer review of Cisplatin
S7397 Sorafenib (BAY 43-9006) Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Mol Cancer, 2025, 24(1):34
Nat Commun, 2025, 16(1):509
Adv Sci (Weinh), 2025, 12(30):e04372
Verified customer review of Sorafenib (BAY 43-9006)
S2111 Lapatinib (GW572016) Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Nat Genet, 2025, 57(6):1452-1462
Cancer Discov, 2025, 10.1158/2159-8290.CD-25-0605
Nat Cancer, 2025, 6(1):67-85
Verified customer review of Lapatinib (GW572016)
S1040 Sorafenib Tosylate (BAY 43-9006) Sorafenib tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Int J Oncol, 2025, 67(3)72
Nature, 2024, 629(8013):927-936
Cell Mol Life Sci, 2024, 81(1):238
Verified customer review of Sorafenib Tosylate (BAY 43-9006)
S1007 Roxadustat (FG-4592) Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. This compound also potentiates RSL3 induced ferroptosis. Phase 3.
Immunity, 2025, S1074-7613(25)00139-6
Cell Stem Cell, 2025, S1934-5909(25)00338-8
Mol Cell, 2025, 85(15):2973-2987.e6
Verified customer review of Roxadustat (FG-4592)
S1792 Simvastatin (MK-733) Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays. Simvastatin induces ferroptosis, mitophagy, autophagy and apoptosis.
Nat Metab, 2025, 7(10):2018-2032
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
J Clin Invest, 2025, e190215
Verified customer review of Simvastatin (MK-733)
S7309 BAY 87-2243 BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. This compound inhibits mitochondrial complex I activity, thus triggering a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis. It exerts antitumor activity. Phase 1.
Cancer Sci, 2025, 116(8):2113-2124
Cancer Sci, 2025, 10.1111/cas.70102
Hum Reprod Open, 2024, 2024(1):hoae002
Verified customer review of BAY 87-2243
S1576 Sulfasalazine Sulfasalazine is a sulfa derivative of mesalazine, used as an anti-inflammatory agent to treat bowel disease and rheumatoid arthritis. This compound is a potent and specific inhibitor of nuclear factor kappa B (NF-κB), TGF-β and COX-2. It induces ferroptosis, apoptosis and autophagy.
Med Oncol, 2024, 41(8):188
Adv Sci (Weinh), 2023, 10(20):e2300517
Proc Natl Acad Sci U S A, 2022, 119(36):e2117396119
S1712 Deferasirox (ICL670) Deferasirox is an iron chelator, also a cytochrome P450 3A4 inducer, Cytochrome P450 2C8 inhibitor, and Cytochrome P450 1A2 inhibitor. Deferasirox-induced iron depletion promotes BclxL downregulation and cell death.
Front Immunol, 2025, 16:1502094
Elife, 2023, 12RP88745
J Transl Med, 2023, 21(1):50
Verified customer review of Deferasirox (ICL670)